Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 4/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20013283 | 1.00 | KMT2A (0.43) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL22199740 | 0.92 | KMT2A (0.48) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL20013097 | 0.88 | KMT2A (0.43) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL20013144 | 0.87 | TLR2 (0.42) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL20013276 | 0.87 | KMT2A (0.42) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL20009559 | 0.85 | KMT2A (0.40) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL20009560 | 0.85 | KMT2A (0.40) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL17747066 | 0.85 | KMT2A (0.52) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL17747064 | 0.85 | KMT2A (0.52) | KMT2AMDM4TP53TLR2MDM2 | |
| SCHEMBL17747075 | 0.85 | KMT2A (0.52) | KMT2AMDM4TP53TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633419-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633419-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885MDM4 672/4885TP53 75/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885MDM4 672/4885TP53 75/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885MDM4 672/4885TP53 75/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885MDM4 672/4885TP53 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.